Inclusion Criteria:

- Age between 18 and 75 years

- Histologically proven pancreatic cancer stage III or IV (T1-3 N1M0 or T1 3N0 1M1)

- No option for resection with curative intent

- At least one measurable or not measurable lesion (according to RECIST)

- No previous chemotherapy or other systemic tumor therapy

- No previous radiation

- Performance-Status 0-2 according to WHO/ECOG

- Life expectancy of at least 3 months

- Adequate kidney-, liver- and bone marrow function, defined as

- Absolute neutrophil count * 1,5 x 109/l

- Hemoglobin * 8 g/dl

- Thrombocytes * 100 x 109/l

- Bilirubin * 2 x upper norm (with liver mets < 5-fold)

- Serum Creatinine * 1,25 x upper norm

- Creatinine clearance > 30 ml/min (Cockroft/Gault)

- Transaminases * 2,5 x upper norm (with liver mets < 5-fold)

- Possibility of regular long-term follow-up

- Negative pregnancy test in women at childbearing age

- All patients must have signed an informed consent before study entry.

Exclusion Criteria:

- Known secondary cancer other than curatively treated basalioma or carcinoma in situ
of the cervix uteri

- Clinically unstable CNS-metastases

- Known hypersensitivity against study medication

- Severe impairment of renal function (creatinine clearance < 30 ml/min)

- Severe impairment of liver function (bilirubin > 2,0 x above upper norm,
transaminases > 2,5 x upper norm, or with known liver metastasis >5 x upper norm)

- Clinically relevant disease of the cardiovascular system or other vital organs

- Known polyneuropathy

- Known DPD-deficiency (screening not required)

- Simultaneous treatment with the antiviral agent sorivudin or chemically related
agents such as brivudin

- Pregnancy, lactation or lack of reliable contraception in women at childbearing age

- Mental disease, drug- or alcohol abuse

- Participation in another clinical trial within the last 4 weeks

- All other diseases which may prevent adequate participation in the trial

- Indication of lack of compliance with study regulations